5-Lipoxygenase Polyclonal Antibody

5-Lipoxygenase (5-LO) is an enzyme encoded by ALOX5 in humans that is involved in leukotriene biosynthesis.¹ It is comprised of an N-terminal regulatory domain and a C-terminal catalytic domain and is primarily expressed in leukocytes. Increases in intracellular calcium levels or cellular stress induce translocation of 5-LO from the cytosol or nucleoplasm, depending on the cell type and 5-LO phosphorylation status, to the nuclear envelope, where it interacts with 5-LO-activating protein (FLAP), which transfers arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) to 5-LO.^1,2 5-LO catalyzes the conversion of arachidonic acid to 5(S)-HpETE (Item No. 44230) and then to leukotriene A₄ (LTA₄).³ Other substrates of 5-LO include 5,8,11,14,17-eicosapentaenoic acid, 5,8,11-eicosatrienoic acid, 5,8-eicosadienoic acid, 12-HpETE, and 15-HpETE. Alox5 knockout mice are protected against arthritis and pulmonary inflammation.² Knockout of Alox5 also protects apolipoprotein E-deficient hyperlipidemic mice from high-fat diet-induced hepatic injury and inflammation.⁴ Levels of 5-LO are elevated in postmortem hippocampus and cortex of patients with Alzheimer's disease.⁵ Cayman's 5-Lipoxygenase Polyclonal Antibody can be used for Western blot and immunohistochemistry applications. The antibody recognizes 5-LO at 78 kDa from human and porcine samples.

WARNING This product is not for human or veterinary use.

1. Rådmark, O., Werz, O., Steinhilber, D., et al. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease. Biochim. Biophys. Acta 1851(4), 331-339 (2015).

2. Martínez-Clemente, M., Clària, J., and Titos, E. The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 14(4), 347-353 (2011).

3. Rådmark, O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 68-69, 211-234 (2002).

4. Martínez-Clemente, M., Ferré, N., González-Périz, A., et al. 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor ɑ-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 51(3), 817-827 (2010).

5. Firuzi, O., Zhuo, J., Chinnici, C.M., et al. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease. The FASEB Journal 22(4), 1169-1178 (2008).

Apostoli, A.J., Skelhorne-Gross, G.E., Rubino, R.E., et al. Loss of PPARcexpression in mammary secretory epithelial cellscreates a pro-breast tumorigenic environment. Int. J. Cancer 134(5), 1055-1066 (2014).

Xie, Z., Bi, C., Cheong, L.L., et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One 6(6), e21583 (2011).

Pfister, S., Somberg, L., Lowry, T., et al. Mechanisms underlying increased reactivity of pulmonary arteries contralateral to a localized high-flow anastomosis. J. Thorac. Cardiovasc. Surg. 141(2), 425-431 (2011).

Wasilewicz, M.P., Kolodziej, B., Bojulko, T., et al. Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis. Int. J. Colorectal Dis. 25(9), 1079-1085 (2010).

Kern, K., Schäfer, S.M.G., Cohnen, J., et al. The G2A receptor controls polarization of macrophage by determining their localization within the inflamed tissue. Front. Immunol. 9, 2261 (2018).